BR112017016067A2 - agentes mucolíticos de monotiol - Google Patents

agentes mucolíticos de monotiol

Info

Publication number
BR112017016067A2
BR112017016067A2 BR112017016067A BR112017016067A BR112017016067A2 BR 112017016067 A2 BR112017016067 A2 BR 112017016067A2 BR 112017016067 A BR112017016067 A BR 112017016067A BR 112017016067 A BR112017016067 A BR 112017016067A BR 112017016067 A2 BR112017016067 A2 BR 112017016067A2
Authority
BR
Brazil
Prior art keywords
mucus
mucolytic
patient
formula
mucolytic agents
Prior art date
Application number
BR112017016067A
Other languages
English (en)
Portuguese (pt)
Inventor
Ross Johnson Michael
R Thelin William
Original Assignee
Parion Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parion Sciences Inc filed Critical Parion Sciences Inc
Publication of BR112017016067A2 publication Critical patent/BR112017016067A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/28—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BR112017016067A 2015-01-30 2016-01-28 agentes mucolíticos de monotiol BR112017016067A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109999P 2015-01-30 2015-01-30
PCT/US2016/015353 WO2016123335A1 (en) 2015-01-30 2016-01-28 Novel monothiol mucolytic agents

Publications (1)

Publication Number Publication Date
BR112017016067A2 true BR112017016067A2 (pt) 2018-04-03

Family

ID=56544326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016067A BR112017016067A2 (pt) 2015-01-30 2016-01-28 agentes mucolíticos de monotiol

Country Status (13)

Country Link
US (2) US10106551B2 (enExample)
EP (1) EP3250548A4 (enExample)
JP (2) JP6826038B2 (enExample)
KR (1) KR20170108088A (enExample)
CN (2) CN112321472A (enExample)
AU (1) AU2016211440B2 (enExample)
BR (1) BR112017016067A2 (enExample)
CA (1) CA2974210A1 (enExample)
IL (1) IL253501B (enExample)
MX (1) MX387071B (enExample)
SG (1) SG11201705790SA (enExample)
WO (1) WO2016123335A1 (enExample)
ZA (1) ZA201705122B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115177626A (zh) 2013-03-14 2022-10-14 加利福尼亚大学董事会 硫代糖粘液溶解剂及其应用和组合物
AU2014309251B2 (en) 2013-08-23 2018-05-24 Parion Sciences, Inc. Dithiol mucolytic agents
CN112321472A (zh) * 2015-01-30 2021-02-05 帕里昂科学公司 新型单硫醇粘液溶解剂
CN107708680A (zh) 2015-04-30 2018-02-16 帕里昂科学公司 新的二硫醇粘液溶解剂的前药
CA3112462A1 (en) 2018-09-10 2020-03-19 The Regents Of The University Of California Dithiolsaccharide mucolytic agents and uses thereof
EP3797783A1 (en) 2019-09-27 2021-03-31 Freie Universität Berlin Novel medical uses of thiol-functionalized polyglycerol derivatives
CN112758902B (zh) * 2021-01-06 2022-01-28 西南科技大学 用于高效析氧反应的优化电子构型Co4N纳米片的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639635A (en) 1969-02-11 1972-02-01 Riker Laboratories Inc Process for the liquefaction of mucus
US3663690A (en) 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
FR2155776B1 (enExample) * 1971-10-04 1974-11-15 Rech Pharmaceut Scient
BE789811A (fr) * 1971-10-07 1973-04-06 Bristol Myers Co 1,4-bis-acylpiperazines
FR2434149A1 (fr) * 1978-06-22 1980-03-21 Parcor Nouveaux derives de la l-cysteine
JPH01226866A (ja) * 1988-03-08 1989-09-11 Wako Pure Chem Ind Ltd メルカプトメチル化方法
FR2685323B1 (fr) * 1991-12-19 1994-04-08 Rhone Poulenc Chimie Mercaptomethylbenzylamines et leur utilisation dans la synthese de bisphenols.
US20010037037A1 (en) 1995-10-31 2001-11-01 Kurt Dietliker Oximesulfonic acid esters and the use thereof as latent sulfonic acids
JP2002012583A (ja) * 2000-04-28 2002-01-15 Sumitomo Chem Co Ltd アミン誘導体の製造方法
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
CA2478089A1 (en) 2002-03-06 2003-09-18 Duke University Methods and composition based on discovery of metabolism of nitroclycerin
WO2003088961A1 (en) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004271945A1 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
PT1663235E (pt) 2003-08-18 2013-10-29 Parion Sciences Inc Novos bloqueadores dos canais do sódio de pirazinoílguanidina protegida
AU2004264441A1 (en) 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
WO2005094269A2 (en) 2004-03-24 2005-10-13 National Jewish Medical And Research Center Mucolytic and anti-elastase compounds and methods of use thereof
US20090324724A1 (en) 2004-08-18 2009-12-31 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
KR20070052317A (ko) 2004-08-18 2007-05-21 마이클 알 존슨. 환형 아미드 및 에스테르 피라지노일구아니딘 나트륨 채널차단제
KR20070059063A (ko) 2004-08-18 2007-06-11 마이클 알 존슨. 지방족 아미드 및 에스테르 피라지노일구아니딘 나트륨채널 차단제
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20090192227A1 (en) 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
CN101415405A (zh) 2006-04-04 2009-04-22 Stc.Unm公司 用于药物递送的可溶胀颗粒
CA2650035C (en) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
WO2007146867A2 (en) 2006-06-09 2007-12-21 Parion Sciences Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
WO2007146870A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
US8163758B2 (en) 2006-06-09 2012-04-24 Parion Sciences, Inc. Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
JP2010502739A (ja) 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善
BRPI0716884A2 (pt) * 2006-09-07 2013-10-15 Parion Sciences Inc Método de intensificação de hidratação mucosal e clearance mucosal através de tratamento com bloqueadores do canal de sódio e osmolitos
CN101534813A (zh) * 2006-09-07 2009-09-16 帕里昂科学公司 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
US20080131500A1 (en) 2006-12-04 2008-06-05 The Board Of Regents Of The University Of Texas System Methods and compositions for rapid inactivation of proteins
WO2008124491A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use taste modulators
WO2008124496A1 (en) 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
WO2009078782A1 (en) 2007-12-19 2009-06-25 Pharmalundensis Ab Method and means for producing bronchorelaxation
KR101654549B1 (ko) 2008-02-26 2016-09-07 패리온 사이언스 인코퍼레이티드 다중방향족 나트륨 채널 차단제
US20100074881A1 (en) 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
US10117906B2 (en) 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
EP2210936A1 (en) 2009-01-27 2010-07-28 Curetis AG Processing and analysis of viscous liquid biological samples
EP2428582B1 (en) 2010-09-14 2013-09-04 miacom Diagnostics GmbH Clearance buffer
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
BR112013032771B1 (pt) 2011-06-27 2021-01-12 Parion Sciences, Inc. dipeptídio quimicamente e metabolicamente estável possuindo potente atividade bloqueadora de canais de sódio
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
DK2855435T3 (en) 2012-05-29 2018-07-16 Parion Sciences Inc DENDRIMER-LIKE AMINOAMIDES WITH SODIUM CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF DRY EYES AND OTHER MILK DISEASES
WO2014036445A2 (en) 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
US9994519B2 (en) 2012-11-28 2018-06-12 Yansong Lu Synthetic antioxidants and their uses
US9029382B2 (en) 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
BR112015014349A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
AU2014309251B2 (en) * 2013-08-23 2018-05-24 Parion Sciences, Inc. Dithiol mucolytic agents
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN104078680B (zh) 2014-05-23 2015-09-09 南京中储新能源有限公司 一种碳硫复合正极及二次铝硫电池
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
FR3024801A1 (fr) 2014-08-08 2016-02-12 Commissariat Energie Atomique Materiau d'electrode positive a base d'un materiau carbone specifique fonctionnalise par des composes organiques specifiques
CN112321472A (zh) 2015-01-30 2021-02-05 帕里昂科学公司 新型单硫醇粘液溶解剂
CN107708680A (zh) 2015-04-30 2018-02-16 帕里昂科学公司 新的二硫醇粘液溶解剂的前药

Also Published As

Publication number Publication date
JP7112464B2 (ja) 2022-08-03
KR20170108088A (ko) 2017-09-26
JP2018505163A (ja) 2018-02-22
MX387071B (es) 2025-03-19
US20190031679A1 (en) 2019-01-31
IL253501A0 (en) 2017-09-28
CA2974210A1 (en) 2016-08-04
SG11201705790SA (en) 2017-08-30
CN107614480B (zh) 2020-09-15
AU2016211440A1 (en) 2017-08-10
ZA201705122B (en) 2021-01-27
WO2016123335A1 (en) 2016-08-04
IL253501B (en) 2021-01-31
CN107614480A (zh) 2018-01-19
AU2016211440B2 (en) 2020-08-27
JP2021004256A (ja) 2021-01-14
EP3250548A4 (en) 2018-07-11
CN112321472A (zh) 2021-02-05
US10968233B2 (en) 2021-04-06
HK1247909A1 (zh) 2018-10-05
JP6826038B2 (ja) 2021-02-03
EP3250548A1 (en) 2017-12-06
US10106551B2 (en) 2018-10-23
MX2017009764A (es) 2018-03-28
US20160222023A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
BR112017016067A2 (pt) agentes mucolíticos de monotiol
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
BR112014032419A2 (pt) polímero a base de etileno, composição, artigo e processo para formar o polímero a base de etileno
MX380643B (es) Composicion para la eliminacion de compuestos que contienen azufre.
BR112014004859A2 (pt) preparação e composições de enxofre zerovalente altamente biodisponíveis e usos das mesmas
BR112017017627A2 (pt) processo para produção de uma composição.
BR112018067995A2 (pt) composição oftalmológica
BR112019007609A2 (pt) ciclobutano 1,3 di-substituído ou derivados de azetidina como inibidores de sintase de prostaglandina d hematopoiética
BR112019004332A2 (pt) géis injetáveis que compreendem ácido hialurônico reticulado e hidroxiapatita, composição e processo de fabricação dos mesmos
BR112018005194A2 (pt) processo de composto antifúngico
BR112017005997A2 (pt) método
BR112015028213A2 (pt) componentes catalisadores para polimerização de olefinas
BR112016021648A2 (pt) novos compostos
BR112014028042A2 (pt) inibidores de nampt
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
MX2016002378A (es) Agentes mucolíticos de ditiol.
UY36348A (es) Derivados de benzotiofenilo sustituidos como agonistas del gpr40 para el tratamiento de la diabetes tipo ii
MX340928B (es) Derivados de oxazolina e isoxazolina como moduladores de canales de calcio de liberación activa (crac).
BR112016020278A8 (pt) Derivados de 1,2-diidro-3h pirrolo[1,2- c]imidazol-3-ona antibacterianos
BR112017008821A2 (pt) hidroxissilano como um promotor de adesão ou agente de reticulação
BR112013024347A2 (pt) composição estabilizadora para polímeros contendo halogênio
BR112017028362A2 (pt) composições aditivas para a eliminação de sulfeto de hidrogênio, e o meio compreendendo as mesmas
MX2016015896A (es) Composiciones que contienen azufre polimerico y usos de estas.
MY182954A (en) Oil-extended rubber, rubber composition, and method for manufacturing the oil-extended rubber
BR112018004879B8 (pt) Processo para remoção de compostos de enxofre de uma corrente de processo e uso de uma solução tendo um teor de matéria seca orgânica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements